| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 31st December 2020 | John W. Higuchi | 1,700 | Open or private sale | $1.35 | $2,286.50 |
| 31st December 2020 | John W. Higuchi | 5,000 | Open or private sale | $1.35 | $6,767.00 |
| 16th December 2020 | Jeffrey Arvin Fink | 5,625 | Exercise of derivative | $0.00 | |
| 16th December 2020 | Mahesh V. Patel | 15,000 | Open or private sale | $1.35 | $20,250.00 |
| 16th December 2020 | Mahesh V. Patel | 45,000 | Exercise of derivative | $0.00 | |
| 16th December 2020 | John W. Higuchi | 3,750 | Exercise of derivative | $0.00 | |
| 16th December 2020 | Morgan R Brown | 8,437 | Open or private sale | $1.35 | $11,389.95 |
| 16th December 2020 | Morgan R Brown | 28,125 | Exercise of derivative | $0.00 | |
| 16th December 2020 | Richard Dana Ono | 5,250 | Exercise of derivative | $0.00 | |
| 16th December 2020 | Stephen A Hill | 7,500 | Exercise of derivative | $0.00 |
Lipocine
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Lipocine, Inc. focuses on the oral testosterone replacement therapy and preterm birth prevention. The company was founded in 2011 and is headquartered in Salt Lake City, UT.
Ticker: LPCN
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1535955
Employees: 12
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
